Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives $12.90 Consensus PT from Brokerages

Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) have been assigned a consensus recommendation of “Moderate Buy” from the eleven ratings firms that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, nine have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $12.90.

A number of analysts have recently weighed in on CMPX shares. D. Boral Capital restated a “buy” rating and issued a $30.00 price objective on shares of Compass Therapeutics in a research note on Wednesday, November 5th. Wall Street Zen upgraded shares of Compass Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. Guggenheim increased their target price on Compass Therapeutics from $10.00 to $12.00 and gave the company a “buy” rating in a research note on Tuesday, August 12th. Compass Point set a $10.00 price target on shares of Compass Therapeutics in a report on Monday, October 6th. Finally, Lifesci Capital assumed coverage on shares of Compass Therapeutics in a research report on Monday, October 6th. They set an “outperform” rating and a $10.00 price objective for the company.

Compass Therapeutics Trading Up 1.3%

Shares of NASDAQ CMPX opened at $4.83 on Thursday. The stock has a fifty day moving average price of $3.90 and a 200 day moving average price of $3.08. Compass Therapeutics has a 12-month low of $1.27 and a 12-month high of $5.05. The company has a market cap of $859.06 million, a P/E ratio of -10.73 and a beta of 1.48.

Compass Therapeutics (NASDAQ:CMPX) last announced its quarterly earnings data on Wednesday, November 5th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.06. On average, sell-side analysts forecast that Compass Therapeutics will post -0.36 EPS for the current fiscal year.

Hedge Funds Weigh In On Compass Therapeutics

A number of hedge funds have recently bought and sold shares of CMPX. Suvretta Capital Management LLC boosted its holdings in shares of Compass Therapeutics by 97.2% in the 3rd quarter. Suvretta Capital Management LLC now owns 14,101,159 shares of the company’s stock valued at $49,354,000 after purchasing an additional 6,951,666 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Compass Therapeutics by 45.6% during the 3rd quarter. Vanguard Group Inc. now owns 7,062,799 shares of the company’s stock worth $24,720,000 after buying an additional 2,212,794 shares during the last quarter. Vivo Capital LLC boosted its stake in Compass Therapeutics by 70.0% in the second quarter. Vivo Capital LLC now owns 6,043,466 shares of the company’s stock valued at $15,713,000 after buying an additional 2,487,443 shares in the last quarter. Adage Capital Partners GP L.L.C. grew its position in Compass Therapeutics by 11.3% in the second quarter. Adage Capital Partners GP L.L.C. now owns 4,424,868 shares of the company’s stock valued at $11,505,000 after acquiring an additional 449,868 shares during the last quarter. Finally, Balyasny Asset Management L.P. acquired a new position in Compass Therapeutics during the third quarter worth about $9,892,000. 68.43% of the stock is owned by institutional investors.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.